Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5644 - Development and validation of a metastasis-associated immune prognostic model for concurrent metastatic colorectal cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Zhiwen Luo


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


Z. Luo, H. Zhao, Z. Li, R. Mao, J. Zhao, D. Ge, F. Zhang, Y. Zhou, X. Chen, J. Cai, X. Bi

Author affiliations

  • Department Of Hepatobiliary Surgery, National Cancer Center/national Clinical Research Center For Cancer/cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5644


The recurrence of concurrent metastatic colorectal cancer (mCRC) after primary surgery and subsequent irinotecan-based therapies is still a challenge. Fong’s CRS criteria prompted us to identify mCRC with high recurrence risk, and whether there are any specific gene signatures identifing those mCRC? Therefore, we aimed to identify gene signatures and investigated how they regulate the mCRC immunophenotype and thus affect the prognosis..


We investigated RNA expression in different populations and platforms. Based on metastasis-related genes, a metastatic evaluation model (MEM) was developed, which divided mCRCs into high and low recurrence risk groups. Further investigation of these two groups made an immune prognostic model (IPM) based on differentially expressed immune-related genes. Then, the influence of the IPM on mCRC’s immune microenvironment was comprehensively analyzed by bioinformatics.


High recurrence risk in mCRC after surgery and subsequent irinotecan-based therapies was attributed to the down-regulation of immune response, which was influenced mainly by 3 metastasis-related genes (BAMBI, F13A1, LCN2) and 3 immune-related genes (SLIT2, CDKN2A, CLU). MEM and IPM were established and validated based on 231 mCRC patients to differentiate patients with a low or high risk of recurrence. A nomogram was established. Functional enrichment analysis showed immune response and immune system diseases pathway represented the major function and pathway, respectively, related to IPM genes. Moreover, we found IPM high-risk group had higher fractions of Tregs and CD8+ T cells, lower fractions of neutrophils and eosinophils, and presented higher expression of CCR8 than low-risk group.


The recurrence of mCRC after primary surgery and subsequent irinotecan-based therapies is strongly related to the immune microenvironment. Our IPM may have important implications for identifying subgroups of mCRC with low or high risk of recurrence, and give new insights in personal chemotherapy and immunotherapy for mCRC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study



Initial Project 2018-1-4021 Beijing Municipal Health Commission.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.